Form 4: Prelude Therapeutics Executive Granted Stock Options

Jane Huang, President and CMO of Prelude Therapeutics, was granted stock options for 200,000 shares on February 4, 2025.

Summary

• Jane Huang, the President and CMO of Prelude Therapeutics, received employee stock options on February 4, 2025.
• The options grant is for 200,000 shares of Prelude Therapeutics common stock.
• The exercise price of the options is $1.11 per share.
• The options vest over time, with 25% vesting on February 4, 2026, and the remainder vesting monthly over the following 36 months, contingent on continued service to the company.
• The options expire on February 4, 2035.

Sentiment

Score: 7

Explanation: The document reflects a standard executive compensation practice, which is generally viewed neutrally to positively as it incentivizes management. There are no red flags or negative implications.

Positives

• The granting of stock options aligns the executive's interests with those of the shareholders.
• The vesting schedule incentivizes continued service and commitment to the company.

Future Outlook

The document does not contain any specific forward-looking statements beyond the vesting schedule of the options.

Industry Context

Stock option grants are a common form of executive compensation in the biotechnology industry, used to attract and retain talent and align their interests with those of shareholders. The vesting schedule is typical for such grants.

Comparison to Industry Standards

• Stock option grants are a standard component of executive compensation packages in the pharmaceutical and biotechnology industries.
• Companies like Amgen, Gilead Sciences, and Biogen routinely use stock options as part of their compensation strategy.
• The vesting schedule of 25% after one year followed by monthly vesting over the next three years is a common practice.
• The size of the grant (200,000 shares) would be benchmarked against similar roles and company size within the biotech sector.

Stakeholder Impact

• Shareholders may view the stock option grant as a positive incentive for the executive.
• Employees may see this as a sign of the company's commitment to its leadership.

Key Dates